Evidence map›Paper›PMID 35082500›Full record

ArticleOncoTargets and therapy2022

Superselective Prostate Artery Embolization for Treatment of Severe Haematuria Secondary to Rapid Progression of Treatment-Induced Neuroendocrine Prostate Cancer: A Case Report.

Liang Deng, Chao Li, Qiangrong He, Chenghui Huang, Qian Chen, Shengwang Zhang, Long Wang, Yu Gan, Zhi Long

Open access · goldAbstract readCase Reports
In one paragraph

Article in OncoTargets and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Liang DengAndrology Center, Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China.
Chao LiAndrology Center, Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China.
Qiangrong HeAndrology Center, Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China.
Chenghui HuangDepartment of Medical Oncology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China.
Qian ChenDepartment of Pathology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China.
Shengwang ZhangDepartment of Radiation Oncology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China.
Long WangAndrology Center, Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China.
Yu GanDepartment of Urology, Xiangya Hospital of Central South University, Changsha, 410008, People's Republic of China.
Zhi LongAndrology Center, Department of Urology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment-induced neuroendocrine prostate cancer (t-NEPC) represents a highly aggressive subtype of castration-resistant prostate cancer that commonly arises from prostate adenocarcinoma (AdPC) after continuous androgen deprivation therapy (ADT). However, current treatments for t-NEPC are limited and far from satisfactory. According to our limited knowledge, report regarding the management of t-NEPC related hemorrhage is rare. Here, we report a case of t-NEPC formation after chronic hormonal therapy accompanying with severe bleeding in primary tumor and share our experiences to deal with the severe hematuria resulting from the progression of t-NEPC tumor. CASE PRESENTATION: An 80-year-old man with a significantly high prostate-specific antigen was diagnosed via pathology as advanced AdPC due to multiple bone metastases. He then received ADT including bicalutamide and goserelin. After 20 months of stable disease, the cancer rapidly progressed and presented with severe gross hematuria caused by bleeding of the primary tumor. The histopathologic analysis of a secondary biopsy of the primary tumor confirmed neuroendocrine prostate cancer, and subsequent genetic testing revealed germ-line mutations in the RB1 and FOXA1. To control the bleeding and relieve symptoms, the patient was treated with superselective prostate artery embolization (PAE). After the left internal pudendal artery and the right prostatic artery were embolized, hematuria was quickly alleviated and disappeared. However, the patient was not a suitable candidate to platinum-based chemotherapy due to weak constitution. Goserelin was continuously applied to maintain castration level of serum testosterone. Meanwhile, palliative radiotherapy to the prostate tumor, high-risk lymph node drainage areas (including iliac and para-aortic lymph nodes, internal iliac lymph nodes, presacral lymph nodes and obturator nerve lymph nodes) and bone metastases (right sacroiliac joint and thoracic vertebra) was performed and relieved the pain. Unfortunately, this patient eventually died of cachexia and multiple organ failure nearly 27 months after initial diagnosis.

conclusionTo treat severe hematuria caused by progression of t-NEPC, superselective PAE may be a rapid and efficient way to stop bleeding.

Indexed as

androgen deprivation therapyprostate cancerradiotherapysuperselective prostate artery embolizationtreatment-induced neuroendocrine prostate cancer

Identifiers

PMID35082500
PMCPMC8786387
OpenAlexW4206768220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.